{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.9","upperLimit":"32.1","value":"26.9"},{"groupId":"OG001","lowerLimit":"16.6","upperLimit":"27.3","value":"23.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the number of months between study enrollment and death from any cause. Patients still alive at the last followup were censored on the date of last CT Scan.\n\nThe product-limit method will be used to estimate the cumulative distribution of overall survival times for the patients assigned to each treatment group.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive a placebo IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim subcutaneously (SC) on days 9-15 or pegfilgrastim SC on day 9 or 10.\n\nDocetaxel: Given IV\n\nFilgrastim: Given SC\n\nGemcitabine Hydrochloride: Given IV\n\nPegfilgrastim: Given SC\n\nPlacebo: Given IV","id":"OG000","title":"Arm I Gem+Doce+Placebo"},{"description":"Patients receive bevacizumab IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10.\n\nBevacizumab: Given IV\n\nDocetaxel: Given IV\n\nFilgrastim: Given SC\n\nGemcitabine Hydrochloride: Given IV\n\nPegfilgrastim: Given SC","id":"OG001","title":"Arm II Gem+Doce+Bev"}],"paramType":"MEDIAN","populationDescription":"All randomized","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}